April 18, 2025
The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who […]
April 17, 2025
TOPLINE: A recent study identified three clinically distinct vitiligo profiles on the basis of Vitiligo Patient Priority Outcomes (ViPPO) responses from real-world patient data. Classes with […]
April 17, 2025
A recent case report explains how epitope spread may cause immune checkpoint inhibitor (ICI)–associated bullous pemphigoid (BP). A separate research letter spotlights cases of partial lipodystrophy […]
April 16, 2025
TOPLINE: A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with […]
April 11, 2025
TOPLINE: An autonomous total body photographic (TBP) and dermoscopic imaging device achieved comparable image quality and faster acquisition times than manual dermoscopy, in a prospective cohort […]
April 11, 2025
By the late 1990s, annual cases of measles in the United States dwindled to a few dozen, down from more than 27,000 in 1990. However, the […]
April 10, 2025
TOPLINE: Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe […]
April 9, 2025
TOPLINE: Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. […]
April 4, 2025
ORLANDO, Fla. — Beyond appropriate use criteria for Mohs surgery outlined by a multidisciplinary ad hoc task force in 2012, choice of treatment for superficial skin […]